Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.

Rolston KVI, Jamal M, Nesher L, Raad I, Rice SA, Rybak MJ, Prince RA.

J Glob Antimicrob Resist. 2019 Jun;17:16-18. doi: 10.1016/j.jgar.2019.02.018. Epub 2019 Mar 5. No abstract available.

PMID:
30844496
2.

In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer.

Rolston KVI, Reitzel R, Vargas-Cruz N, Shelburne SA, Raad II, Prince RA.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):351-353. doi: 10.1016/j.diagmicrobio.2018.03.009. Epub 2018 Mar 16.

PMID:
29661529
3.

In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients.

Rolston KVI, Jamal MA, Nesher L, Shelburne SA, Raad I, Prince RA.

Int J Antimicrob Agents. 2017 Apr;49(4):416-421. doi: 10.1016/j.ijantimicag.2016.12.016. Epub 2017 Feb 28.

PMID:
28257904
4.

Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients.

Rolston KV, Wang W, Nesher L, Smith JR, Rybak MJ, Prince RA.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):338-342. doi: 10.1016/j.diagmicrobio.2016.12.010. Epub 2016 Dec 16.

PMID:
28109549
5.

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KVI, Jones RN, Castanheira M, Chemaly RF.

Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.

PMID:
27313265
6.

In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.

Rolston KV, Wang W, Nesher L, Shelburne SA, Prince RA.

J Antibiot (Tokyo). 2016 May;69(5):381-7. doi: 10.1038/ja.2015.120. Epub 2015 Dec 2.

PMID:
26626876
7.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7823-5. doi: 10.1128/AAC.01021-15. Epub 2015 Sep 21.

8.

In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.

Rolston K 6th, Wang W, Nesher L, Coyle E, Shelburne S, Prince RA.

J Antibiot (Tokyo). 2014 Jul;67(7):505-9. doi: 10.1038/ja.2014.30. Epub 2014 May 14.

PMID:
24824818
9.

Reply to Nation et al.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Dec;57(11):1657-8. doi: 10.1093/cid/cit525. Epub 2013 Aug 9. No abstract available.

PMID:
23934308
10.

Polymyxins: wisdom does not always come with age.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Sep;57(6):877-83. doi: 10.1093/cid/cit367. Epub 2013 Jul 11. Review.

PMID:
23728146
11.

Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.

Rolston KV, Kapadia M, Tarrand J, Coyle E, Prince RA.

Int J Antimicrob Agents. 2013 Jun;41(6):516-20. doi: 10.1016/j.ijantimicag.2013.01.014. Epub 2013 Mar 6.

PMID:
23481658
12.

High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.

Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP.

J Antimicrob Chemother. 2013 May;68(5):1148-51. doi: 10.1093/jac/dks521. Epub 2013 Jan 24.

PMID:
23349440
13.

Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.

Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, Prince RA, Wang W, Raad II.

Transplantation. 2012 Aug 15;94(3):302-8. doi: 10.1097/TP.0b013e3182577485.

PMID:
22814329
14.

Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.

Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP.

Virulence. 2011 Jul-Aug;2(4):348-55. Epub 2011 Jul 1.

PMID:
21788730
15.

Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.

Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP.

J Antimicrob Chemother. 2011 Jun;66(6):1324-31. doi: 10.1093/jac/dkr142. Epub 2011 Apr 11.

PMID:
21486855
16.

Escherichia coli resistance to quinolones at a comprehensive cancer center.

Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV.

Diagn Microbiol Infect Dis. 2010 Jul;67(3):266-9. doi: 10.1016/j.diagmicrobio.2010.02.014. Epub 2010 May 15.

PMID:
20471765
17.

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.

Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH.

J Infect Dis. 2010 Mar 15;201(6):889-97. doi: 10.1086/651024.

PMID:
20156065
18.

Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.

Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP.

Antimicrob Agents Chemother. 2010 Mar;54(3):1298-304. doi: 10.1128/AAC.01222-09. Epub 2009 Dec 28.

19.

Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.

Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH.

J Antimicrob Chemother. 2009 Sep;64(3):556-62. doi: 10.1093/jac/dkp247. Epub 2009 Jul 9.

PMID:
19589810
20.

Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma.

Tam VH, Hou J, Kwa AL, Prince RA.

J Antimicrob Chemother. 2009 Mar;63(3):627-8; author reply 628-9. doi: 10.1093/jac/dkn483. Epub 2008 Nov 19. No abstract available.

PMID:
19022780
21.

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VH.

Antimicrob Agents Chemother. 2008 Aug;52(8):2898-904. doi: 10.1128/AAC.01309-07. Epub 2008 May 27.

22.

Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.

Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN.

Arch Ophthalmol. 2008 Jan;126(1):18-22. doi: 10.1001/archophthalmol.2007.8.

PMID:
18195213
23.

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.

Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. Epub 2007 Dec 10.

24.

Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH.

Diagn Microbiol Infect Dis. 2008 Feb;60(2):163-7. Epub 2007 Oct 4.

PMID:
17916420
25.
26.

Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP.

Antimicrob Agents Chemother. 2007 Mar;51(3):1078-81. Epub 2006 Dec 28.

27.

Vitreous and aqueous penetration of orally administered moxifloxacin in humans.

Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, Gao H, Prince RA.

Arch Ophthalmol. 2006 Feb;124(2):178-82.

PMID:
16476886
28.

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE.

Antimicrob Agents Chemother. 2006 Feb;50(2):469-73.

29.

Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.

Hariprasad SM, Shah GK, Chi J, Prince RA.

J Cataract Refract Surg. 2005 Nov;31(11):2142-6.

PMID:
16412929
30.

In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.

Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP.

J Antimicrob Chemother. 2006 Feb;57(2):288-93. Epub 2005 Dec 30.

PMID:
16387749
31.

Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center.

Lewis RE, Wiederhold NP, Lionakis MS, Prince RA, Kontoyiannis DP.

J Clin Microbiol. 2005 Dec;43(12):6120-2.

32.
33.

Subcutaneous administration of cefepime.

Walker P, Neuhauser MN, Tam VH, Willey JS, Palmer JL, Bruera E, Prince RA.

J Pain Symptom Manage. 2005 Aug;30(2):170-4.

PMID:
16125032
34.

Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.

Wiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE.

J Antimicrob Chemother. 2005 May;55(5):792-5. Epub 2005 Apr 6.

PMID:
15814598
35.

Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Hariprasad SM, Mieler WE, Shah GK, Blinder KJ, Apte RS, Holekamp NM, Thomas MA, Chi J, Prince RA.

Trans Am Ophthalmol Soc. 2004;102:149-55; discussion 155-7.

36.

The distinct and secondary harmful effect of pelvic and extremity injury on the outcome of laparotomy for trauma.

Prince RA, Hoffman CJ, Scanlan RM, Mayberry JC.

J Surg Res. 2005 Mar;124(1):3-8.

PMID:
15734472
37.

Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA.

Arch Ophthalmol. 2005 Jan;123(1):39-44.

PMID:
15642810
38.

Detection of gliotoxin in experimental and human aspergillosis.

Lewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, Kontoyiannis DP, Prince RA.

Infect Immun. 2005 Jan;73(1):635-7.

39.

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE.

J Infect Dis. 2004 Oct 15;190(8):1464-71. Epub 2004 Sep 10.

PMID:
15378439
40.

Treatment of meningeal coccidioidomycosis with caspofungin.

Hsue G, Napier JT, Prince RA, Chi J, Hospenthal DR.

J Antimicrob Chemother. 2004 Jul;54(1):292-4. Epub 2004 Jun 9. No abstract available.

PMID:
15190025
41.

Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.

Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA.

Arch Ophthalmol. 2004 Jan;122(1):42-7.

PMID:
14718293
42.

Sensory regulation of swallowing and airway protection: a role for the internal superior laryngeal nerve in humans.

Jafari S, Prince RA, Kim DY, Paydarfar D.

J Physiol. 2003 Jul 1;550(Pt 1):287-304. Epub 2003 May 16.

43.

Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.

Lewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA.

Antimicrob Agents Chemother. 2002 Nov;46(11):3499-505.

44.
45.

Chest radiograph heterogeneity predicts functional improvement with volume reduction surgery.

Baldwin JC, Miller CC 3rd, Prince RA, Espada R.

Ann Thorac Surg. 2000 Oct;70(4):1208-11.

PMID:
11081872
46.

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV.

Antimicrob Agents Chemother. 2000 Oct;44(10):2915-8.

47.

Effect of a dual-lumen peripheral catheter on the delivery of known incompatible medications.

Prince RA, Lucas DS, Fox JL.

Ann Pharmacother. 1998 Sep;32(9):875-7.

PMID:
9762372
49.

A simple method for administering vancomycin in the spinal cord injured population.

Griver AR, Prince RA, Darouiche RO.

Arch Phys Med Rehabil. 1997 May;78(5):459-62.

PMID:
9161361
50.

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J, Bodey GP.

J Infect Dis. 1995 Aug;172(2):599-602.

PMID:
7622915

Supplemental Content

Loading ...
Support Center